Solid Biosciences Inc SLDB
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
Trading Information
- Previous Close Price
- $9.63
- Day Range
- $9.35–9.59
- 52-Week Range
- $3.80–11.44
- Bid/Ask
- $9.49 / $9.53
- Shares Outstanding
- 98.45M
- Market Cap
- $933.30M
- Volume/Avg
- 341,552 / 2M
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- —
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Total Yield
- —
Company Profile
Solid Biosciences Inc is a life sciences company focused on advancing a portfolio of current and future gene therapy candidates, including SGT-003 for the treatment of Duchenne muscular dystrophy, SGT-212 for the treatment of Friedreich's ataxia, SGT-501 for the treatment of catecholaminergic polymorphic ventricular tachycardia, SGT-601 for the treatment of TNNT2-mediated dilated cardiomyopathy, and additional assets for the treatment of genetic cardiac and neuromuscular diseases. The majority of its current programs are designed to treat these diseases with gene transfer products. The company operates in a single segment, developing treatments through gene therapy and other means for patients with neuromuscular and cardiac diseases.
- Sector
- Healthcare
- Industry
- Biotechnology
- Stock Style Box
- Small Value
- Total Number of Employees
- 121
- Website
- https://www.solidbio.com
Valuation
|
Metric
|
SLDB
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | 2.53 |
Price/Sales | — |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
SLDB
|
|---|---|
Quick Ratio | 12.57 |
Current Ratio | 13.10 |
Interest Coverage | — |
Quick Ratio
SLDB
Profitability
|
Metric
|
SLDB
|
|---|---|
Return on Assets (Normalized) | −52.80% |
Return on Equity (Normalized) | −63.03% |
Return on Invested Capital (Normalized) | −61.64% |
Return on Assets
SLDB
Biotechnology Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Vertex Pharmaceuticals Inc
VRTX
| LOCK|p#PBPW | LOCK|&rh& | $121B | |||
| Regeneron Pharmaceuticals Inc
REGN
| LOCK|#D$VV^F | LOCK|c%?% | $69B | |||
| argenx SE ADR
ARGX
| LOCK|pRylyRN | LOCK|@>z | $54B | |||
| Alnylam Pharmaceuticals Inc
ALNY
| LOCK|MP#DCb | LOCK|DtW%G | $38B | |||
| BeOne Medicines Ltd ADR
ONC
| LOCK|%wz#^g | LOCK|QDK | $36B | |||
| Moderna Inc
MRNA
| LOCK|yl#js! | LOCK|NT | $27B | |||
| Royalty Pharma PLC Class A
RPRX
| LOCK|<GP!<#R | LOCK|>Jf># | $25B | |||
| Incyte Corp
INCY
| LOCK|VRp?c@@ | LOCK|^$N | $23B | |||
| BioNTech SE ADR
BNTX
| LOCK|ddd>MLC | LOCK|?r | $23B | |||
| BridgeBio Pharma Inc
BBIO
| LOCK|yPVhs&m | LOCK|g# | $16B |
United States